Mitigare® (colchicine) and its authorized generic may offer an affordable prevention option for your patients with gout. Compared to other colchicine products, Mitigare® has seen only a 4.7 percent price increase over a 4 year period. Since the launch of Mitigare® in 2013, the price of Colcrys®, has increased by a total of 36.47 percent.Affordable treatment option: Compared to other colchicine products, Mitigare® has seen only a 4.7 percent price increase over a 4 year period. Since the launch of Mitigare® in 2013, the price of Colcrys®, has increased by a total of 36.47 percent.*Calculation based on the Consumer price Index Inflation Calculator, available at https://www.bls.gov/data/inflation_calculator.htm. Pricing assumptions: Daily WAC for all agents calculated based on a daily dosing of 1.2 mg for prophylaxis of gout flares. Data included with permission and copyrighted by First Databank, Inc. Exported 6.1.2017.

Coverage By Most Major Plans

Mitigare® (colchicine) is covered by most major health plans, including:

  • United Health Group, Inc.
  • Aetna, Inc.
  • CVS Caremark Rx
  • Express Scripts PBM
  • Cigna Health Plans, Inc.
  • CVS SilverScript

Managed Markets Insight & Technology, LLC database and formulary status as of October 2017. 

 

The True Blue Savings Program

West-Ward Pharmaceuticals (now known as Hikma Pharmaceuticals USA Inc.) developed the True Blue Savings program for Mitigare® to help make effective gout flare prevention for eligible adults even more affordable. With the Mitigare® True Blue Savings co-pay card, your eligible patients can receive Mitigare® free for 30 days and get $5 refills.

For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are free only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. See complete Terms and Conditions

References

  1. PriceRx for Wholesalers. Wolters Kluwer website. Available at: http://www.wolterskluwercdi.com/wholesalers-pricerx/. Accessed November 30, 2016.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.